Cornercap Investment Counsel Inc. Sells 48,525 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Cornercap Investment Counsel Inc. lowered its stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 50.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,763 shares of the company’s stock after selling 48,525 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in Lyell Immunopharma were worth $66,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Lyell Immunopharma by 1.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock worth $15,013,000 after purchasing an additional 92,594 shares in the last quarter. Opaleye Management Inc. acquired a new position in shares of Lyell Immunopharma in the 1st quarter valued at approximately $7,482,000. TD Asset Management Inc lifted its holdings in shares of Lyell Immunopharma by 4.2% during the 2nd quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock worth $1,457,000 after acquiring an additional 40,800 shares during the period. Invenomic Capital Management LP boosted its position in shares of Lyell Immunopharma by 16.8% during the 1st quarter. Invenomic Capital Management LP now owns 871,525 shares of the company’s stock worth $1,944,000 after acquiring an additional 125,110 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Lyell Immunopharma by 6.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock worth $974,000 after acquiring an additional 38,487 shares in the last quarter. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

LYEL stock opened at $1.11 on Tuesday. The stock has a market cap of $309.93 million, a price-to-earnings ratio of -1.41 and a beta of -0.47. The company has a 50 day simple moving average of $1.21 and a 200 day simple moving average of $1.66. Lyell Immunopharma, Inc. has a 1 year low of $0.85 and a 1 year high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.03. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The company had revenue of $0.03 million during the quarter. On average, equities research analysts anticipate that Lyell Immunopharma, Inc. will post -0.8 EPS for the current fiscal year.

Analyst Ratings Changes

LYEL has been the subject of several recent analyst reports. Bank of America cut Lyell Immunopharma from a “buy” rating to an “underperform” rating and cut their target price for the stock from $6.00 to $1.00 in a research note on Wednesday, October 30th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research report on Tuesday, November 12th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.